Among CLL patients, SARS-CoV-2-specific IgG and IgA levels were significantly higher in NCP-positive individuals compared to those who were NCP-negative (Supplementary Figure S2A,B), suggesting that infection may augment antigen-specific antibody response in CLL. The gene discussed is CD79A; the disease is B-cell chronic lymphocytic leukemia.